Amneal Pharmaceuticals, Inc. 4

Co-CEO Chintu Patel acquired 6,381,734 shares of Amneal Pharmaceuticals Class A Common Stock indirectly via limited liability companies as stock consideration in the Kashiv BioSciences acquisition.

On August 10, 2026, Amneal Pharmaceuticals Co-CEO Chintu Patel, through limited liability companies he manages, received 6,381,734 shares of Amneal Pharmaceuticals, Inc. Class A Common Stock as equity consideration in connection with Amneal’s acquisition of Kashiv BioSciences, LLC, in which a subsidiary of the issuer purchased all of Kashiv’s membership interests for $375 million in cash plus 28,942,098 Amneal Class A shares. The transaction is reported as an acquisition of indirect beneficial ownership rather than an open-market purchase, and the filing notes that these shares are held indirectly by limited liability companies, while additional indirect and direct Class A holdings are reported through family trusts and direct ownership. No sale of shares by the reporting person occurred; instead, this represents a large, non-routine equity issuance tied to an M&A transaction, materially increasing Patel’s indirect ownership stake in the company.

Filing Facts

CIK

1723128

Ticker

AMRX

Form

4

Source Type

fda

Accession

0001628280-26-056297

Alert Tier

7